𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials

✍ Scribed by Shuzou Tanimoto; Patrick W. Serruys; Leif Thuesen; Dariusz Dudek; Bernard de Bruyne; Bernard Chevalier; John A. Ormiston

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
206 KB
Volume
70
Category
Article
ISSN
1522-1946

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-in-human implantation of a fully b
First-in-human implantation of a fully bioabsorbable drug-eluting stent: The BVS poly-L-lactic acid everolimus-eluting coronary stent
✍ John A. Ormiston; Mark W.I. Webster; Guy Armstrong 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 1 views

## Abstract The first‐in‐human fully bioabsorbable drug‐eluting stent (BVS poly‐L‐lactic acid everolimus‐eluting coronary stent) implantation was performed at Auckland City Hospital, New Zealand as part of the ABSORB trial. There were no adverse events in‐hospital or by 1 month. A stent that suppor

Four-year clinical follow-up of the XIEN
Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial
✍ Scot Garg; Patrick W. Serruys; Karine Miquel-Hebert; on behalf of the SPIRIT II 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 2 views

## Abstract This report describes the 4‐year clinical outcomes of the SPIRIT II study, which randomized 300 patients to treatment with the XIENCE V everolimus‐eluting stent (EES), or the TAXUS paclitaxel‐eluting stent. At 4‐year clinical follow‐up, which was available in 256 (85.3%) patients, treat